Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
davanat + 5-fluorouracil + leucovorin + bevacizumab
- Development stage
- Discontinued
- Lead developer
- Galectin Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Davanat + 5-fluorouracil + leucovorin + bevacizumab** is a multi-agent chemotherapy regimen investigated primarily in oncology, notably for metastatic colorectal cancer. Davanat is a galactomannan polymer developed to enhance the efficacy and reduce the toxicity of 5-fluorouracil (5-FU), a pyrimidine analog antimetabolite that inhibits thymidylate synthase. Leucovorin (folinic acid) is used to increase the activity of 5-FU by stabilizing its binding to thymidylate synthase. Bevacizumab is a humanized monoclonal antibody that targets and inhibits vascular endothelial growth factor A (VEGF-A), blocking angiogenesis necessary for tumor growth and metastasis[1][3][5].
- Other names
- 5-FUfluorouracilfolinic acidDavanatbevacizumab
02
Targets
LGALS1 (Galectin-1)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on davanat + 5-fluorouracil + leucovorin + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on davanat + 5-fluorouracil + leucovorin + bevacizumab.